Kolistimetatnatrium Accord (Colistimethate Sodium)

Colistimethate sodium binds to lipopolysaccharides and phospholipids in the outer membrane of Gram‑negative bacteria, disrupting membrane integrity. This causes leakage of cellular contents and rapid bacterial cell death without needing intracellular activation.

The dosage of Kolistimetatnatrium Accord is determined by the prescribing clinician based on infection severity, pathogen susceptibility, patient weight, and renal function. Healthcare professionals set the appropriate regimen for each individual case.

Safety data for colistimethate sodium in pregnancy and lactation are limited. It should be used only if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where needed) and import documentation.

Kolistimetatnatrium (colistimethate sodium) is a pro‑drug of colistin, similar to other polymyxins in spectrum and toxicity. Compared with polymyxin B, it is administered intravenously as a sodium salt and may have a slightly different dosing conversion, but both share comparable efficacy against resistant Gram‑negative bacteria.

The product should be stored at 2‑8 °C, kept refrigerated, protected from light, and must not be frozen or shaken. Maintaining the cold‑chain ensures stability of the injectable solution.

Kolistimetatnatrium Accord is supplied as a sterile solution for injection and is administered intravenously by a healthcare professional. The infusion rate and duration are set by the prescriber according to the patient’s clinical condition.

The most serious risks include nephrotoxicity, which can lead to acute kidney injury, and neurotoxicity, which may cause respiratory paralysis or seizures. Prompt monitoring of renal function and neurological status is essential during therapy.

Patients with known hypersensitivity to colistimethate sodium or any component of the formulation should avoid this product. Caution is also advised for individuals with pre‑existing severe renal impairment, neuromuscular disorders, or those receiving other nephrotoxic or neurotoxic agents.